The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations have been identified. However, targeted therapies have very limited activity in unselected SCCHN and the current treatment strategy is still based on tumor location and disease stage and not on tumor biology.
Introduction
Squamous cell carcinoma of the head and the neck (SCCHN) is the seventh most common malignancy [1] . The main risk factors are smoking and alcohol consumption, which are responsible for the majority of SCCHN occurring in the oral cavity, pharynx, and larynx.
Another risk factor for oropharyngeal cancer (OPC) is the human papillomavirus (HPV).
Tobacco and/or alcohol-induced SCCHN and HPV-related OPC are two separate entities with different clinical and molecular features [2] [3] [4] .
Less than 60% of the patients with locally-advanced SCCHN remain disease-free at 3 years, despite a multimodal treatment combining surgery and/or (chemo)radiation [5] . Patients with recurrent/metastatic disease that are not amenable to radiotherapy or surgery have a median survival of 10-12 months. Platinum-based chemotherapy in combination with cetuximab improves overall survival (OS) in the first-line treatment of incurable disease [6] .
Nivolumab increases OS of patients who progress after platinum therapy [7] . Pembrolizumab is also approved in the same indication by the Food and Drug Administration (FDA) [8] . No standard of care exists for patients who progress after platinum-therapy and antiprogrammed cell death protein 1 (PD-1) compounds.
The current treatment strategy of patients with SCCHN is still based on tumor location and disease stage and not on tumor biology [4, 9, 10] . Targeted therapies have shown disappointing results [11] [12] [13] . Trying to select upfront the patients who will benefit from a specific treatment might improve the outcome. The European Organization for Research and Treatment of Cancer (EORTC) is conducting the EORTC-1559-HNCG trial, the first international biomarker-driven umbrella trial in recurrent SCCHN. In this paper, we will review the different trial designs for biomarker-driven studies with their respective advantages and opportunities but also the potential pitfalls that led to the design of the EORTC 1559 protocol. We will also discuss the scientific and logistic challenges of this trial.
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Lessons learned from previous biomarker-driven studies Study designs "Master protocol" terminology refers to a framework in which several (sub)studies that investigate multiple therapies are operated in parallel under one 'overarching' master protocol [14] . Master protocols include two different study designs: basket and umbrella trials. Table 1 summarizes the opportunities and drawbacks of these designs.
Basket trials are biomarker-driven clinical trials that include patients based on pre-defined specific molecular tumor abnormalities, irrespective of tumor origin and histology ( Table 2) .
One of the advantages of this histology agnostic approach is to investigate the activity of targeted drugs across different cancer types, even in rare cancers for which clinical trials do not exist. They also offer the possibility to target low incidence molecular alterations.
Umbrella trials are biomarker-driven clinical trials that are histology specific, investigating different therapeutic interventions in a single cancer type (Table 3) . A histology specific approach is interesting to avoid the heterogeneity due to different biology across various tumor types.
Strategy trials investigate if selecting the treatment based on molecular alterations results
in superior outcome compared to standard therapy, independently of the drug, the disease, and the studied biomarker(s).
Molecular screening programs have been implemented to facilitate the access to precision medicine trials. These screening initiatives can be histology-agnostic or histology-specific.
Theranostic and molecular screening tools
Different diagnostic tests are routinely used to predict the activity or resistance of some targeted therapies. Most of them are evaluated on tumor biopsies, although liquid biopsies are entering into the clinic (e.g. Epidermal Growth Factor Receptor (EGFR) T790M mutation in non-small cell lung cancers (NSCLC)). Biomarkers can be evaluated at the proteomic level such as the estrogen receptor status assessed by immunohistochemistry (IHC) but also at the genomic level such as Human Epidermal Receptor-2 (HER2) amplifications or EGFR activating mutations.
The tumor molecular profile has been obtained in 74% to 93% of screened patients in biomarker-driven clinical trials [16, [18] [19] [20] [21] [22] [23] . Most of them use DNA sequencing on tumor biopsies. Reproducibility and reliability of the molecular screening tools are important. Most of the trials use certified laboratories, but the analysis is not always centralized. In these cases, some trials performed an inter-laboratory analytical validation before starting the trial [24] or validated the assay [25] .
A fresh biopsy is probably more reliable than an archival one. Indeed, the cancer molecular profile can change during disease evolution [26] . IMPACT [18, 21] used archival paraffinembedded tissue (FFPE). In the LUNG-MAP trial [27] and LUNG-MATRIX trial [23] , both archival or fresh-taken tissues are accepted. In the MOSCATO 01 [20] , NCI-MPACT [15] , NCI-MATCH [15] , BATTLE [16] , and SHIVA [17] trials, a fresh tumor biopsy has/had to be taken for the trial purpose.
Actionable genomic alteration frequency and enrolment rate
According to ESMO glossary [28] , targetable genomic alteration encodes an altered protein against which a drug exists or can be synthesized and an actionable genomic alteration includes both targetable alterations and genomic alterations that cannot be directly targeted but that lead to dysregulation of a pathway in which there are possible targets.
The percentage of patients that had an actionable genomic alteration identified through screening programs ranged from 46% to 63% [18, 20, 21, 29] . However, the number of patients who were finally treated with a matched targeted therapy were low: 13%, 16%, and 19% in SAFIR01 [29] , IMPACT (first published report [21] ), and MOSCATO 01 [20] , respectively. This number increased to 27% in the most recent IMPACT publication [18] , probably related to the extension of the screening panels. Different reasons may explain these low enrolment rate: tumor tissue issues, decline in the performance status or rapidly progressing disease, the absence of a targetable event, and the access to matched clinical 7 trials or drugs. As IMPACT and the MOSCATO 01 were screening programs, patients were referred to enrolling clinical trials with obvious limitations in the treatment possibilities.
A way to partially solve these issues is to include the access to drugs into the clinical trial design. The NCI-MATCH basket trial pre-planned the access to some targeted compounds.
However, only 12% of the patients were finally enrolled in the trial [22] . This low enrolling rate might be due to the low incidence of the targeted variants since only 18% of the screened tumors were found to have a genomic alteration that matched one of the 30 treatment arms. In contrast, in BATTLE and LUNG-MAP, two umbrella trials for NSCLC, 75%
and 37% of the patients were included in one of the sub-studies, respectively [16, 27] . The number of treated patients is higher in these two last trials due to a pre-planned access to matched targeted therapies. In addition, for the Battle trial, the molecular profile strategy was disease-specific and adapted to NSCLC, explaining the high prevalence of some of the investigated biomarkers.
Treatment efficacy in Master protocols
Treatment selection based on DNA biomarkers has proven its efficiency: anti-HER2 therapies for HER2 amplified breast cancer [30] and EGFR or pan-HER inhibitors for EGFR mutated NSCLC [31] . Pembrolizumab has been approved, independently of the tumor type, for microsatellite instability-high and mismatch repair deficient cancers [32] as well as for the first-line treatment of metastatic NSCLC with high PD-L1 expression [33] .
Different endpoints are used in biomarker-driven trials. In MOSCATO 01 [20] , the primary endpoint was the progression-free survival (PFS) ratio calculated for each patient, that must be > 1.3 to define clinical benefit (PFS ratio = PFS on the molecular-profile selected therapy/PFS on prior therapy). The approach is judged efficient if it modifies the natural history of the disease and is associated with a longer PFS than the previous line of treatment. Thirty-three percent of patients treated with a targeted therapy had a PFS ratio > 1.3. However, the number of patients who benefited from the personalized approach represented only 7% of the screened patients.
In IMPACT, the clinical outcomes of patients with molecular aberrations treated with matched therapy were compared with those of consecutive patients who were not treated 8 with a matched therapy. They reported a better objective response rate (ORR) (11% vs 5%), a longer failure-free survival (3.4 vs 2.9 months), and a longer OS (8.4 vs 7.3 months) in the matched group [18] . The clinical benefit rate in the matched group, defined as the proportion of patients with either a stable disease lasting more than 6 months or a partial response or complete response, was 29% (111/381) as compared to 24% (56/238) in the non-matched group. However, only 8% of the whole population finally experienced a clinical benefit. The use of non-optimal targeted drugs or sub-optimal dosages in phase 1 trials, and sometimes the level of evidence concerning the investigated biomarker(s) may explain the limited treatment efficacy observed.
In MyPathway basket trial [34] , the ORR was 23% in 14 different tumor types, a clinically significant result for advanced refractory disease. In the SUMMIT trial [35] , a basket trial studying neratinib in patients with a tumor harboring either HER2 or HER 3 mutations, the primary endpoint was reached only for breast cancer, and not for lung, bladder, and colorectal cancers, underlining the importance of the histology and the tissue of cancer origin. In BATTLE [16] , the 8-week disease control rate and ORR were 46% and 4%, respectively. The first data of the ongoing Lung-MAP trial reported an ORR of 4-7% for the first 3 biomarker-driven cohorts [27] .
The SHIVA trial was the first randomized trial comparing a molecularly targeted therapy based on tumor molecular profiling versus conventional therapy for advanced cancer [17] .
This study tested the overall strategy of a biomarker-driven treatment approach versus standard therapy. The trial did not meet its primary endpoint (PFS). Several reasons could explain this overall negative result. First, they used drugs that were marketed in France at that time and not necessarily the best in class to target the molecular alteration identified.
Second, the experimental arm was also heterogeneous with multiple drugs and various tumor types. This could have blinded the benefit of some drugs in some specific cancer(s).
The ongoing NCI-MPACT trial [15] is also a strategy trial. To avoid a negative trial linked with inadequate target modulation by the selected agents, all the targeted agents used in NCI-MPACT have been validated to engage their purported targets and have at least an established phase II dose.
Biomarker-driven studies for SCCHN
Only a few biomarker-driven trials are dedicated to SCCHN (table 4) inactivate respectively p53 and Rb, PIK3CA amplifications/mutations are found in 56%
whereas the other genomic alterations are rare.
The EORTC-1559-HNCG trial (UPSTREAM: Personalized
STrategy for REcurrent And/or Metastatic SCCHN)
Our main objective was to design a biomarker-driven study dedicated to SCCHN patients.
Below, we describe the overall study design as well as the different treatment cohorts.
EORTC-1559-HNCG design
The EORTC-1559-HNCG trial is a biomarker-driven umbrella trial that enrolls patients with recurrent/metastatic SCCHN, progressing after first-line platinum-based chemotherapy. Each patient must undergo a fresh tumor biopsy. NGS is performed to identify somatic mutations and copy number alterations with a custom panel that has been designed for the trial. This Based on the molecular alterations identified, each patient is allocated to one of the cohorts.
If the patient is not eligible for one of the biomarker-driven cohorts, he/she is included in one of the immunotherapy cohorts. The global design of the trial as well as the molecular rules for treatment allocation and prioritization are depicted in figures 1 and 2.
The full protocol includes a core protocol and several addenda. The core protocol describes the overall study design, the objectives and endpoints, the inclusion/exclusion criteria, the study flow chart, the statistical hypotheses, the data analysis plan, and the biobanking processes. For each experimental treatment, there is one separate addendum that contains the confidential information related to the drug. The national health regulatory authorities, the ethical committee, and the investigators have access to the core protocol and all the addenda. The pharmaceutical companies have access to the core protocol but they can view and comment only the addendum/addenda concerning the cohort(s) for which they are supporting.
EORTC-1559-HNCG biomarker-driven and immunotherapy cohorts
Each patient cohort is designed as a phase II study with its own statistical hypothesis ( Table   5 ). The primary endpoint is either ORR or PFS rate. Sample sizes vary from 32 to 76 patients across cohorts. The study can be amended to add other cohorts based on drug availabilities or other biomarker hypotheses.
Pan-human epidermal growth factor receptor (HER) inhibitor cohorts
EGFR mutations/amplifications are described in 15% of HPV-negative SCCHN and HER2 is altered (mutation/amplification) in 5%.
The ORR with cetuximab monotherapy is 13% [37] . In contrast to colon cancer where RAS mutations are predictive markers of resistance, RAS alterations are found in only 4% of HPVnegative SCCHN. Although RAS mutations might also play a role in cetuximab resistance in SCCHN [38] , other mechanisms including activation of other HERs are involved [39, 40] .
Pan-HER inhibitors target all the dimers forms by HER family and have the potential to overcome anti-EGFR therapy resistance caused by cross-talk between EGFR and the other HERs. In unselected SCCHN patients who progress after platinum therapy, afatinib, an irreversible pan-HER inhibitor, improves PFS compared with methotrexate: median PFS 2.7 versus 1.6 months [41] . However, afatinib does not increase OS. Biomarkers analyses were performed within this trial [36] . Median PFS favored afatinib in patients with p16-negative, EGFR-amplified (defined as ≥ 50% of cells with ≥ 4 copies, or ≥1 cell with ≥ 8 copies), HER3-low (defined as H-score ≤ 50), and PTEN-high (defined as H-Score > 150) tumors. In the MCC15780 trial where 38 SCCHN patients were treated with cetuximab [42] , PFS was also significantly increased in PTEN-high tumors compared to PTEN-low tumors [43] . The fact that afatinib seemed to be more active in case of HER3-low and PTEN-high disease suggests that pan-HER inhibitors could be more active when the PI3K pathway is not or less activated.
Cetuximab-naïve patients with p16 negative tumor had also a significant benefit from afatinib (ORR: 27%).
We designed two biomarker-driven cohorts in the EORTC-1559 trial where the patients are randomized between afatinib or investigator's choice. The first cohort includes patients with p16 negative SCCHN harboring either an EGFR mutation/amplification or HER2 mutation/amplification or PTEN high (H-score > 150). We did not include patients with HER3 low disease as this IHC is not always reproducible [44] . The second cohort includes cetuximab-naïve SCCHN patients with p16-negative tumor. SCCHN with any RAS mutations are excluded [38] .
Fibroblast growth factor receptor (FGFR) inhibitor cohorts
FGFRs can activate the RAS-MAPK, PI3K, STAT, and PLCγ pathways [45] . FGFR1 We will investigate Rogaratinib in cases of high FGFR mRNA levels assessed by NGS.
Cell cycle inhibitor cohort
The vast majority of HPV-negative SCCHN harbors genetic alterations (TP53 mutations, Therefore, other immunotherapy approaches have to be investigated.
HLA-E is a non-classical major histocompatibility complex molecule that constitutes a way for cancer cells to escape immune surveillance. HLA-E is highly expressed in 70% of SCCHN [54].
HLA-E binds to NKG2A receptor on NK cells and T-lymphocytes to inhibit the cytotoxic functions of CD8+ T lymphocytes and NK cells. Monalizumab is a human IgG4 antibody targeting the NKG2A receptor. In the first immunotherapy cohort, patients will receive monalizumab monotherapy. In the second immunotherapy cohort, patients will be randomized to receive the combination of durvalumab and monalizumab versus monalizumab monotherapy versus physician's choice.
EORTC1559 Feasibility
The 
Discussion
The EORTC-1559-HNCG trial is the first European international umbrella trial assessing a personalized treatment strategy for patients with recurrent/metastatic SCCHN. We hypothesize that this approach can improve patients' outcome.
The trial design has different strong points: one single protocol with pre-planned access to matched targeted therapies, one fresh tumor biopsy to deal with tumor evolution over time,
an ISO-certified central laboratory, well-defined biomarker hypotheses, and the possibility to have a never-ending protocol with the opportunity of adding new cohorts.
Besides the inherent complexity of such trials, numerous logistic and scientific challenges were encountered when designing this protocol.
Although the pharmaceutical companies accepted the concept of having only one protocol including the different compounds, complex negotiations were crucial to successfully achieve that all stakeholders agreed (i) to standardize the processes, (ii) to accept the pre- In the current design, immunotherapy cohorts are not linked to biomarker(s). Among others, HPV-positivity, PD-L1 overexpression, in-frame or frameshift alterations of specific tumor suppressor genes, and mutational burden are potential biomarkers that have been associated with a higher efficacy of immunotherapy in SCCHN [7, 8, 58] . However, these predictive markers are far to be optimal. Umbrella trials represent an ideal platform to further investigate the predictive value of immune biomarkers.
We cannot deny that tumor heterogeneity that can cause treatment resistance is not addressed by the use of targeted compounds in monotherapy. Therefore, we also collect whole blood, plasma as well as tumor biopsies for translational research. Analyzing these biological samples will give us more insight on the genetic landscape of recurrent/metastatic SCCHN, which may lead to the discovery of new therapeutic targets, and may help to investigate more precisely the utility of liquid biopsy. Translational research will also provide information regarding drug resistance mechanisms and will help us to develop new combination treatments that are able to tackle them.
A finding of biomarker-driven studies is the low number of patients who benefit from this approach. This suggests that for heterogeneous cancers with multiple potential oncogenic drivers, biomarkers assessed only at the DNA level may not predict drug responses reliably.
The signification of some genomic alterations can vary from one cancer histology to another.
Therefore, for further developments, we will have to take into account several others parameters such as the phenotype (e.g. gene expression/proteomic profiles) and the tissue of cancer origin [59] .
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In conclusion, precision medicine remains a major challenge for the medical community.
Large efforts are needed to optimize the study designs, the theranostic tools, and the trial logistics. Designing biomarker-driven studies requires close collaboration with country competent authorities, ethics committees, and pharmaceutical companies to reduce the administrative burden and facilitate the processes linked with the design and conduct of such clinical trials. 
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